Skip to main content

Table 4 Prognostic analysis of DFS and OS for GISTs of the small intestine in terms of immunohistochemical features

From: Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate

Variable   Mean DFS (ms; 95%CI of mean) P Mean OS (ms; 95%CI of mean) P
CD117 (KIT) Focally positive (N = 12) 40.1 (18.3–61.9) 0.1276 77.8 (39.9–115.6) 0.2159
  Diffusely positive (N = 73) 74.4 (54.0–94.7)   101.6 (79.1–124.3)  
KIT immunopattern Diffuse cytoplasmic stain (N = 55) 80.8 (54.6–107.0) 0.0981 95.5 (70.9–120.1) 0.8628
  Mixed with "golgi pattern" (N = 30) 51.6 (33.1– 70.1)   99.4 (69.1–129.7)  
CD34 Negative (N = 25) 64.8 (44.9–84.6) 0.4806 87.5 (64.7–110.4) 0.2242
  Focally positive (N = 28) 55.9 (34.6–77.2)   70.6 (48.2–93.0)  
  Diffusely positive (N = 32) 81.0 (50.6–111.4)   116.9 (84.4–149.2)  
SMA Negative (N = 36) 76.3 (44.4–108.3) 0.1866 101.2 (70.5–132.0) 0.0637
  Focally positive (N = 17) 45.4 (24.3– 66.5)   56.8 (34.6–78.9)  
  Diffusely positive (N = 32) 82.0 (60.7–103.2)   106.8 (82.2–131.4)  
S-100 Negative (N = 34) 81.9 (49.9–113.9) 0.1274 104.9 (75.8–133.9) 0.3896
  Focally positive (N = 31) 64.5 (44.6–84.5)   79.8 (60.6–99.0)  
  Diffusely positive (N = 20) 48.4 (22.43–74.3)   78.6 (43.4–113.9)  
Ki-67 index < 10% (N = 80) 73.6 (53.9–93.4) 0.0014 99.4 (78.5–120.2) 0.0171
  10% (N = 5) 13.8 (6.8–20.8)   24.0 (13.0–35.0)  
  1. DFS = disease-free survival; OS = overall survival; GISTs = gastrointestinal stromal tumors